MAGNIFY - Pulmonary Magnetic Resonance Imaging for Cystic Fibrosis

A regiszterben nem jelölt feltételek

• General Inclusion criteria
• For eligibility into MAGNIFY, subjects should meet all of the following criteria:
• A confirmed clinical diagnosis of CF, consisting of 2 confirmed disease-causing CFTR mutations along with either positive sweat chloride (>60mmol/L, measured before starting CFTR modulator therapy) or a clinical picture consistent with CF as judged by a senior CF physician. Patients will be under one of named regional CF centres above.
• Be able to attend the local facility for scans (Royal Hallamshire Hospital, Sheffield).
  • For eligibility into 129Xe-MRI and lung function (cohort 1,2 and 3)
• Aged 5 years and above
• FEV1 >30% predicted (best in the previous 6 months) For eligibility for cohort 1
• Previous participation in the MMAVIC study, with at least one prior visit where lung ventilation MRI was successfully measured.
  • For eligibility into cohort 4 for 1H MRI only:
• Aged between 1 and 5 years of age
  • General Exclusion criteria
  • Patients who meet any of the following criteria will be excluded from the study. Further exclusions may be applied at the discretion of the principal investigators.
• Previous lung transplant.
• Infection with organisms of the Burkholderia cepacia complex, MRSA or Mycobacterium abscessus.
• Pregnancy.
• Resting SpO2 < 90% in room air.
• Inability to comfortably lie supine for more than 60 minutes.
• Any contraindication(s) to MRI scanning as per the MRI questionnaire used in clinical practice by the University of Sheffield MRI unit, Royal Hallamshire Hospital.
  • Research visit (temporary) exclusion criteria
• Pulmonary exacerbation within 4 weeks as defined by no new treatments in that time, no clinically significant change in their symptoms or spirometry (as judged by attending physician).
• Pregnancy. Patients who become pregnant prior to consent or during the study can remain in the study. However, no research visits will take place during pregnancy.